tiprankstipranks
Seres Therapeutics price target lowered to $10 from $12 at Chardan
The Fly

Seres Therapeutics price target lowered to $10 from $12 at Chardan

Chardan lowered the firm’s price target on Seres Therapeutics (MCRB) to $10 from $12 and keeps a Buy rating on the shares after Seres and partner Nestle Health Sciences (NSRGY) announced the FDA approval of VOWST, formerly SER-109, for the treatment of recurrent C. difficile Infection, or rCDI,in adults following antibacterial treatment. The approval of VOWST "was not a surprise" given the supportive safety and efficacy data from the phase 3 trial, says the firm, which cites initial WAC pricing of $17,500 per course of treatment, which was lower than the $25,000 the firm had assumed, for its lower target.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on MCRB:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles